Delivery Order SPE2DB22D3016-SPE2DB25FBJM8
- Not listed
- The Defense Logistics Agency awarded a $49,957.75 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Yervoy 200 mg/40 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award represents a child delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,435.46 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Yervoy 50 mg/10 ml vials. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 20, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA....
- The Defense Logistics Agency awarded a $25,022.41 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Yervoy 200 mg/40 mL vials. The contract represents a firm fixed-price delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply...
- The Defense Logistics Agency awarded a $17,153.19 delivery order to AmerisourceBergen Drug Corp for Yervoy (ipilimumab) 50 mg/10 mL vials on August 21, 2025, with an ultimate completion date of September 12, 2025. This non-competitive delivery order operates under a firm fixed price structure and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Yervoy is a checkpoint inhibitor immunotherapy commonly used in cancer treatment, reflecting the...
- The Defense Logistics Agency awarded a $11,435.46 delivery order to AmerisourceBergen Drug Corp for Yervoy 50 mg/10 mL vials. This delivery order, issued on September 4, 2025, represents a competitive, non-set-aside award with firm fixed pricing and an ultimate completion date of September 25, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. Yervoy is an immunotherapy medication used in cancer treatment, reflecting the Defense...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Yervoy 50 mg/10 mL vials with a ceiling value of $11,435.46 under a firm fixed-price contract type. This non-set-aside award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026. The delivery is scheduled to be completed...
- The Defense Logistics Agency awarded a $13,499.88 delivery order to AmerisourceBergen Drug Corp for Yervoy 50 mg/10 ml vials, with a completion date of June 24, 2025. This competitive, firm fixed-price delivery order represents a non-set-aside procurement supporting the federal government's pharmaceutical supply requirements. The contract will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $37,864.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of YERVOY (ipilimumab) 200 mg/40 mL vials. The contract, awarded on May 12, 2025, with an ultimate completion date of June 3, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of YERVOY (ipilimumab) 50 mg/10 mL vials, with a contract ceiling value of $22,870.92. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through competitive procurement. The contract is set to be completed by September 30, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract award, valued at $40,996.83, is for the supply of Yervoy 50 mg/10 ml vials. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBJM8Delivery Order
The Defense Logistics Agency awarded a $95,786.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Yervoy (ipilimumab) 200 mg/40 mL vials. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion master agreement extending through December 2026 that serves as the primary pharmaceutical supply vehicle for military healthcare systems worldwide. The award was made without a set-aside designation on a competitive basis, with performance to be executed from the vendor's Conshohocken, Pennsylvania facility with an ultimate completion date of October 7, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated substantial capability in fulfilling federal medical procurement requirements across multiple therapeutic categories. As a critical vendor for the Defense Health Agency and other federal healthcare systems, the company maintains a comprehensive portfolio supporting military and veteran healthcare needs through delivery of specialty medications, brand-name and generic pharmaceuticals, and specialized medical supplies. This award of the immunotherapy agent Yervoy reflects the company's ongoing role in ensuring pharmaceutical availability for defense medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $95.8k | 9/16/25 |